Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data regarding cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,529,560 new cancer cases and 569,490 deaths from cancer are projected to occur in the United States in 2010. Overall cancer incidence rates decreased in the most recent time period in both men (1.3% per year from 2000 to 2006) and women (0.5% per year from 1998 to 2006), largely due to decreases in the 3 major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and 2 major cancer sites in women (breast and colorectum). This decrease occurred in all racial/ethnic groups in both men and women with the exception of American Indian/Alaska Native women, in whom rates were stable. Among men, death rates for all races combined decreased by 21.0% between 1990 and 2006, with decreases in lung, prostate, and colorectal cancer rates accounting for nearly 80% of the total decrease. Among women, overall cancer death rates between 1991 and 2006 decreased by 12.3%, with decreases in breast and colorectal cancer rates accounting for 60% of the total decrease. The reduction in the overall cancer death rates translates to the avoidance of approximately 767,000 deaths from cancer over the 16-year period. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, geographic area, and calendar year. Although progress has been made in reducing incidence and mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons younger than 85 years. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population and by supporting new discoveries in cancer prevention, early detection, and treatment. CA Cancer J Clin 2010;60:277-300.
Introduction
Cancer is a major public health problem in the United States and many other parts of the world. Currently, 1 in 4 deaths in the United States is due to cancer. In this article, we provide an overview of cancer statistics, including updated incidence, mortality, and survival rates, and expected numbers of new cancer cases and deaths in 2010.
Materials and Methods

Data Sources
Mortality data from 1930 to 2007 in the United States were obtained from the National Center for Health Statistics (NCHS). 1 Incidence data for long-term trends , 5-year relative survival rates, and lifetime probability of developing cancer were obtained from the Surveillance, Epidemiology, and End Results (SEER) program of the *Rounded to the nearest 10; estimated new cases exclude basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.
About 54,010 female carcinoma in situ of the breast and 46,770 melanoma in situ will be newly diagnosed in 2010. †Estimated deaths for colon and rectum cancers are combined. ‡More deaths than cases may reflect lack of specificity in recording underlying cause of death on death certificates or an undercount in the case estimate. ‡  340  100  100  410  120  150  580  180  Ohio   §  64,450  8,280  410  5,960  2,010  1,810  10,710  2,200  2,720  8,010  2,970  Oklahoma  478.3  18,670  2,300  150  1,730  460  560  3,250  640  810  2,440  770  Oregon  471.2  20,750  2,910  130  1,710  600  530  2,810  1,200  930  3,010  1,040  Pennsylvania  503.7  75,260 10,000  540  7,440  2,450  2,070  10,520  3,550  3,430  9,800  4,050  Rhode Island  515.5  5,970  790   ‡  540  190  160  840  290  240  740  350  South Carolina  476.4  23,240  3,260  170  2,140  560  590  3,970  1,060  950  3,600  950  South Dakota  460.2  4,220  530   ‡  450  130  130  540  170  180  760  230  Tennessee   §  33,070  4,700  270  3,130  750  850  5,980  1, State-specific incidence rates were obtained from NAACCR based on data collected by cancer registries participating in the SEER program and the NPCR. 6 Population data were obtained from the US Census Bureau. 7 Causes of death were coded and classified according to the International Classification of Diseases (ICD-8, ICD-9, and ICD-10). [8] [9] [10] Cancer cases were classified according to the International Classification of Diseases for Oncology. 11 
Estimated New Cancer Cases and Deaths
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because cancer case reporting is incomplete in some states. Furthermore, the most recent year for which incidence and mortality data are available lags 3 to 4 years behind the current year due to the time required for data collection and compilation. Therefore, we project the expected number of new cancer cases and deaths in the United States in 2010 to provide an estimate of the current cancer burden. Estimated new cancer cases in the current year (2010) were projected using a spatiotemporal model based on incidence data from 1995 through 2006 from 44 states and the District of Columbia that met the NAACCR's high-quality data standard for incidence, covering approximately 89% of the US population. 12 The method also considers geographic variations in sociodemographic and lifestyle factors, medical settings, and cancer screening behaviors as predictors of incidence, and accounts for expected delays in case reporting. We used the state-space prediction method to estimate the number of cancer deaths expected to occur in the United States and in each state in the year 2010. 13 Projections are based on underlying cause-of-death from death certificates as reported to the NCHS. 
Other Statistics
We provide mortality statistics for the leading causes of death as well as deaths from cancer in the year 2007. Causes of death for 2007 were coded and classified according to This report also provides updated statistics regarding trends in cancer incidence and mortality rates, the probability of developing cancer, and 5-year relative survival rates for selected cancer sites based on data from 1975 through 2006. 2, 6 All age-adjusted incidence and death rates are standardized to the 2000 US standard population and expressed per 100,000 population. The incidence rates (2002) (2003) (2004) (2005) (2006) and long-term trends are adjusted for delays in reporting when possible. Delayed reporting primarily affects the most recent 1 to 3 years of incidence data (in this case, 2004-2006), especially for cancers such as melanoma, leukemia, and prostate that are frequently diagnosed in outpatient settings. The NCI has developed a method to account for expected reporting delays in SEER registries for all cancer sites combined and many specific cancer sites. 14 Delay-adjusted rates provide a more accurate assessment of trends in the most recent years for which data are available. Long-term incidence and mortality trends for selected cancer sites were previously published in the 2010 Annual Report to the Nation on the Status of Cancer. 15 We also provide the contribution of individual cancer sites to the total decrease in overall cancer death rates since 1990 in men and 1991 in women and estimates of the total number of cancer deaths avoided because of the reduction in overall age-standardized cancer death rates through 2006. The total number of cancer deaths avoided was calculated by applying the age-specific 1975  1977  1979  1981  1983  1985  1987  1989  1991  1993  1995  1997  1999  2001  2003  2005  1975  1977  1979  1981  1983  1985  1987  1989  1991  1993  1995  1997  1999  2001 cancer death rates in the peak year for the agestandardized cancer death rates (1990 for males and 1991 for females) to the corresponding age-specific populations in the subsequent years through 2006 to obtain the number of expected deaths in each calendar year if the death rates had not decreased. We then summed the difference between the number of expected and observed deaths in each age group and calendar year for men and women separately to obtain the total number of cancer deaths avoided over the 15-year (women) or 16-year (men) interval.
Selected Findings
Expected Numbers of New Cancer Cases in 2010 Table 2 . Figure 1 indicates the most common cancers expected to occur in men and women in 2010. Among men, cancers of the prostate, lung and bronchus, and colorectum account for 52% of all newly diagnosed cancers. Prostate cancer alone accounts for 28% (217,730) of incident cases in men. Based on cases diagnosed between 1999 and 2005, an estimated 92% of these new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which the 5-year relative survival approaches 100%. The 3 most commonly diagnosed types of cancer among women in 2010 will be cancers of the breast, lung and bronchus, and colorectum, accounting for 52% of estimated cancer cases in women. Breast cancer alone is expected to account for 28% (207,090) of all new cancer cases among women.
Expected Number of Cancer Deaths in 2010
Table 1 also shows the expected number of deaths from cancer projected for 2010 for men, women, and both sexes combined. It is estimated that approximately 569,490 Americans will die from cancer, corresponding to greater than 1500 deaths per day. Cancers of the lung and bronchus, prostate, and colorectum in men, and cancers of the lung and bronchus, breast, and colorectum in women continue to be the most common fatal cancers. These 4 cancers account for approximately half of the total cancer deaths among men and women (Fig. 1) . Lung cancer surpassed breast cancer as the leading cause of cancer death in women in 1987 and is expected to account for 26% of all female cancer deaths in 2010. Table 3 provides the estimated number of cancer deaths in 2010 by state for selected cancer sites. Table 4 depicts cancer incidence rates for selected cancer sites by state. By far, the largest variation in incidence among the cancer sites listed in Table 4 is for lung cancer, for which rates (cases per 100,000 population) range from 37.8 in men and 23.0 in women in Utah to 133.1 in men and 76.9 in women in Kentucky. This variation reflects the large and continuing differences in smoking prevalence among states. Utah ranks lowest in adult smoking prevalence and Kentucky highest. In contrast, state variation in the incidence rates of other cancer sites shown in Table 4 is smaller in both absolute and proportionate terms. For screenable cancers, such as those of the prostate and female breast, variation in incidence rates reflects differences in the use of screening tests in addition to differences in disease occurrence.
Regional Variations in Cancer Rates
Trends in Cancer Incidence and Mortality
Figures 2 to 5 depict long-term trends in cancer incidence and death rates for all cancers combined and for selected cancer sites by sex. Table 5 shows incidence and mortality patterns for all cancer sites and for the 4 most common cancer sites based on join point analysis. Trends in incidence were adjusted for delayed reporting. Delay-adjusted cancer incidence rates decreased by 1.3% per year from 2000 through 2006 in males and by 0.5% per year from 1998 through 2006 in females. 15 Incidence trends decreased for all 4 major cancer sites except for lung cancer in women, in whom rates are still increasing, though at a much slower rate than in previous years. The lag in the temporal trend of lung cancer rates in women compared with men reflects historical differences in cigarette smoking between men and women; cigarette smoking in women peaked approximately 20 years later than in men. The accelerated decrease in colorectal cancer incidence rates from 1998 to 2006 largely reflects increases in screening that can detect and remove precancerous polyps. 15 The decrease in prostate cancer incidence rates (by 2.4% per year from [16] [17] [18] The decrease in the breast cancer incidence rate since 1999 likely reflects the large discontinuity in the use of menopausal hormone therapy among postmenopausal women beginning in 2001, and it may also reflect delayed diagnosis due to decreased mammography use. [19] [20] However, close inspection of incidence data by individual year (Fig. 3) *Death rates for cancer peaked in 1990 in men and in 1991 in women. †This calculation is based on each cancer site's contribution to the increasing or decreasing portion of the total cancer death rate, depending on the individual site's trend; it does not represent the contribution to the net decrease in cancer death rates.
Death rates for all cancer sites combined decreased by 2. (Table 5) . Mortality rates have continued to decrease across all 4 major cancer sites in both men and women, except for female lung cancer, for which rates stabilized from 2003 to 2006 after increasing for many decades. Table 6 shows the contribution of individual cancer sites to the decreasing portion of the total cancer death rate for Note: Percentages may not total 100 due to rounding. In accordance with the National Center for Health Statistics' cause-of-death ranking, "Symptoms, signs, and abnormal clinical or laboratory findings" and categories that begin with "Other" and "All other" were not ranked. Note: Deaths within each age group do not sum to all ages combined due to the inclusion of unknown ages. In accordance with the National Center for Health Statistics' cause-of-death ranking, "Symptoms, signs, and abnormal clinical or laboratory findings" and categories that begin with "Other" and "All other" were not ranked. each sex. Death rates from all cancers combined peaked in 1990 for men and in 1991 for women. Between 1990-1991 and 2006, death rates for cancer decreased by 21.0% among men and by 12.3% among women. Among men, reduction in death rates from lung, prostate, and colorectal cancers accounted for nearly 80% of the total decrease in the cancer death rate, whereas reduction in death rates from breast and colorectal cancers accounted for 60% of the decrease noted among women. Lung cancer in men and breast cancer in women each account for nearly 40% of the sex-specific decreases in cancer death rates. The decrease in lung cancer death rates among men is due to a reduction in tobacco use over the past 50 years, whereas the decrease in death rates for female breast, colorectal, and prostate cancer largely reflects improvements in early detection and/or treatment. 
Recorded Number of Deaths from Cancer in 2007
A total of 562,875 cancer deaths were recorded in the United States in 2007, the most recent year for which actual data are available, accounting for approximately 23% of all deaths (Table 7 ) . Despite a decrease in age-standardized death rates, from 180. all age groups among both males and females; it is the leading cause of death among men and women ages 40 to 79 years (Table 9) . Cancer is the leading cause of death among men and women aged younger than 85 years (Fig. 6) . A total of 475,211 persons aged younger than 85 years died from cancer in the United States in 2007, compared with 380,791 deaths from heart disease, which is the leading cause of death overall in the United States. 1 Table 10 presents the number of deaths from all cancers combined and from the 5 most common cancer sites for each 20-year age group. Among males aged younger than 40 years, leukemia is the most common fatal cancer, whereas cancer of the lung and bronchus predominates in men aged 40 years and older.
Colorectal cancer is the second most common cause of cancer death among men ages 40 to 79 years, and prostate cancer among men aged 80 years and older. Among females, leukemia is the leading cause of cancer death before age 20 years, breast cancer ranks first at ages 20 to 59 years, and lung cancer ranks first at ages 60 years and older.
Cancer Occurrence by Race/Ethnicity
Cancer incidence and death rates vary considerably among racial and ethnic groups (Table 11) , although the extent of variation may be affected by misclassification of race and ethnicity on medical records, including death certificates. 26 For all cancer sites combined, African American men have a 14% higher incidence rate and a 34% higher death rate than white men, whereas African American women have a 7% lower incidence rate, but a 17% higher death rate than white women. For the specific cancer sites listed in Table 11 , incidence and death rates are consistently higher in African Americans compared with whites except for cancers of the breast (incidence) and lung (incidence and mortality) among women, and kidney (mortality) among both men and women. Factors known to contribute to racial disparities in mortality vary by cancer site and include differences in exposure to underlying risk factors (eg, historical smoking prevalence for lung cancer among men), access to high-quality screening (breast, cervical, and colorectal cancers), and timely diagnosis and treatment. The higher breast cancer incidence rates observed among white women are believed to reflect a combination of factors that affect both diagnosis (eg, more frequent mammography in white women) and underlying disease occurrence (eg, later age at first birth and greater use of menopausal hormone therapy among white compared with black women). 21 Cancer incidence and death rates are lower in other racial and ethnic groups than in whites and African Americans for all cancer sites combined and for the 4 most common cancer sites. However, incidence and death rates for cancer sites related to infectious agents, such as those of the uterine cervix, stomach, and liver, are generally higher in minority populations than in whites. Stomach and liver cancer incidence and death rates are twice as high in Asian American/Pacific Islanders compared with whites, reflecting an increased prevalence of chronic infection with Helicobacter pylori and hepatitis B and C viruses, respectively, in this population. 22 Kidney cancer death rates are the highest among American Indians/Alaskan Natives; the higher prevalence of obesity and smoking in this population may contribute to this disparity. 16 Trends in cancer incidence can be adjusted for delayed reporting only in whites and African Americans because the long-term incidence data required for delay adjustment are not available for other racial and ethnic subgroups. From 1997 through 2006, incidence (unadjusted for delayed reporting) and death rates for all cancer sites combined decreased among whites, African Americans, Asian Americans/Pacific Islanders, and Hispanics in both males and females. Among American Indians/Alska Natives residing in Indian Health Service Contract Health Service Delivery Areas, incidence and mortality rates decreased in men but remained stable in women during this time period. 15 16 ‡Persons of Hispanic/Latino origin may be of any race.
Year of Death
Source: Edwards, et al. 15 Lifetime Probability of Developing Cancer
The lifetime probability of being diagnosed with an invasive cancer is higher for men (44%) than women (38%) (Table 12 ). However, because of the earlier median age of diagnosis for breast cancer compared with other major cancers, women have a slightly higher probability of developing cancer before age 60 years. These estimates are based on the average experience of the general population and may overestimate or underestimate individual risk because of differences in exposure and/or genetic susceptibility.
Cancer Survival By Race
Compared with whites, African American men and women have poorer survival once cancer is diagnosed.
The 5-year relative survival is lower in African Americans than in whites for every stage of diagnosis for nearly every cancer site (Fig. 8) . These disparities may result from inequalities in access to and receipt of quality health care and/or from differences in comorbidities. As shown in Figure 9 , African Americans are less likely than whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated. The extent to which factors other than stage at diagnosis contribute to the overall differential survival is unclear. 23 However, some studies suggest that African Americans who receive cancer treatment and medical care similar to that of whites experience similar outcomes. 24 There have been notable improvements since 1975 in the relative 5-year survival rates for many cancer sites for both whites and African Americans (Table 13) . Cancers for which survival has not improved substantially over the past 30 years include those of the lung and pancreas. The improvement in survival reflects a combination of earlier diagnosis and improved treatments.
Relative survival rates cannot be calculated for racial and ethnic populations other than whites and African Americans because accurate life expectancies (the average number of years of life remaining for persons who have attained a given age) are not available. However, based on causespecific survival rates of cancer patients diagnosed between 1999 and 2005 in SEER areas of the United States, all minority male populations have a greater probability of dying from cancer within 5 years of diagnosis than whites. Among women, African Americans have the lowest 5-year, cancerspecific survival (55.8%), followed by American Indians/ Alaska Natives (60.0%), whites (65.5%), Hispanics (66.4%), and Asians/Pacific Islanders (68.0%). 2 For all 4 L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t A ll S t a g e s L o c a li z e d R e g io n a l D is t a n t major cancer sites (prostate, female breast, lung and bronchus, and colorectum), minority populations are generally more likely to be diagnosed at distant stage, compared with whites ( Fig. 9) . 25 
